New England Research & Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-13,625
| Closed | -$958K | – | 149 |
|
|
2024
Q3 | $958K | Buy |
13,625
+4,550
| +50% | +$320K | 0.45% | 72 |
|
|
2024
Q2 | $747K | Sell |
9,075
-6,275
| -41% | -$517K | 0.36% | 88 |
|
|
2024
Q1 | $1.34M | Buy |
+15,350
| New | +$1.34M | 0.66% | 51 |
|
|
2023
Q2 | – | Sell |
-9,550
| Closed | -$929K | – | 138 |
|
|
2023
Q1 | $929K | Buy |
+9,550
| New | +$929K | 0.54% | 71 |
|
|
2022
Q2 | – | Sell |
-9,363
| Closed | -$722K | – | 155 |
|
|
2022
Q1 | $722K | Buy |
9,363
+4,351
| +87% | +$336K | 0.37% | 85 |
|
|
2021
Q4 | $443K | Buy |
+5,012
| New | +$443K | 0.21% | 117 |
|
|
2021
Q1 | – | Sell |
-6,750
| Closed | -$592K | – | 170 |
|
|
2020
Q4 | $592K | Buy |
+6,750
| New | +$592K | 0.37% | 89 |
|
|
2019
Q3 | – | Sell |
-3,150
| Closed | -$270K | – | 165 |
|
|
2019
Q2 | $270K | Sell |
3,150
-350
| -10% | -$30K | 0.18% | 142 |
|
|
2019
Q1 | $311K | Buy |
+3,500
| New | +$311K | 0.21% | 128 |
|
|
2018
Q4 | – | Sell |
-5,500
| Closed | -$533K | – | 157 |
|
|
2018
Q3 | $533K | Buy |
+5,500
| New | +$533K | 0.35% | 101 |
|